Show All

April 2012

Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, Noble CO, Lücker PB, Zandstra PW, Drummond DC, Olivier KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, and Wickham TJ

HER2-targeted Liposomal Doxorubicin Displays Enhanced Anti-tumorigenic Effects without Associated Cardiotoxicity

Toxicol Appl Pharmacol 262(1):1-10

Publication Date: April 21, 2012

Product Type: iCell Cardiomyocytes


iCell Cardiomyocytes were used to support the assertion that HER-2 targeted liposomal doxorubicin does not induce cardiotoxicity. Data were included in an Investigational New Drug (IND) application submitted to the FDA.


iCell Cardiomyocytes provided a relevant human model system to advance a new drug candidate through the drug development pipeline. This is the first known instance of data generated using an iPS cell-derived model being used to support an IND filing to the FDA.